SequelSEC

Unicycive Therapeutics, Inc. UNCY

Pharmaceutical Preparations · CIK 0001766140 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2023-12-31
Operating income
-$6.31M
Fiscal year ended 2023-12-31
Free cash flow
-$4.44M
Fiscal year ended 2023-12-31

Unicycive Therapeutics, Inc. (UNCY) reported revenue of $0 and net income of -$7.80M for the fiscal year ended 2023-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Unicycive Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Unicycive Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-30
Revenue$0$0$0$675.00K$0$951.00K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$6.31M-$5.94M-$4.32M-$4.20M-$5.32M-$5.55M
Net income-$7.80M-$4.33M-$3.84M-$14.58M-$5.33M-$5.56M
Research & development$4.23M$3.37M$2.27M$3.03M$3.84M$4.80M
Weighted-average diluted sharesUnavailableshares 32.63Mshares 15.23Mshares 15.23MUnavailableshares 15.06M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailable$-0.13$-0.29$-0.97Unavailable$-0.37
Selling, general & administrativeUnavailable$479.00K$193.00K$62.00K-$164.00K$163.00K
General & administrative$2.08M$2.57M$2.06M$1.85M$1.48M$1.70M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Unicycive Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-30
Cash & equivalentsUnavailable$14.34M$18.82M$24.33M$455.00K$7.01M
Total assets$14.19M$19.44M$22.88M$27.20M$2.82M$10.18M
Current assets$13.40M$18.57M$21.93M$26.18M$2.64M$9.96M
Total liabilities$18.00M$16.01M$16.05M$16.68M$3.28M$5.55M
Current liabilities$17.53M$15.46M$15.42M$15.97M$3.28M$5.52M
Total equity incl. NCI-$3.81M$3.43M-$19.37M-$15.08M-$466.00K$4.63M
Temporary (mezzanine) equityUnavailableUnavailable$26.20MUnavailableUnavailableUnavailable
InventoryUnavailableUnavailable$3.11M$1.85M$2.19M$2.95M
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$839.00K$1.08M$503.00K$790.00K$892.00K$2.29M

Cash flow

Unicycive Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-30
Operating cash flow-$4.44M-$4.42M-$5.50M-$3.92M-$6.08MUnavailable
Capital expenditures$0$0UnavailableUnavailable$0Unavailable
Investing cash flow$0$0UnavailableUnavailable$0Unavailable
Financing cash flow-$205.00K-$51.00K$0$27.80MUnavailableUnavailable
Net change in cashUnavailableUnavailable-$5.51M$23.88M-$6.56MUnavailable
Stock-based compensation$550.00K$929.00K$144.00K$144.00K$197.00K$266.00K
Common dividends paid$0$100.00K$600.00K$200.00KUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Unicycive Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-30
Free cash flow-$4.44M-$4.42MUnavailableUnavailable-$6.08MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable-622.5%Unavailable-584.0%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable21.3%Unavailable28.0%
Current ratio0.76x1.20x1.42x1.64x0.81x1.80x
Revenue YoY growthUnavailable-100.0%UnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailable-584.3%
R&D / revenueUnavailableUnavailableUnavailable448.9%Unavailable505.0%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open UNCY in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2023-03-31

Difference 25599000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.